Growth Hormone in Neuroendocrine Dysfunction With Severe Fibromyalgia Syndrome

Inclusion Criteria: * Women aged greater than or equal (\>=) 18 years * Fibromyalgia diagnosed at least one year before * History of generalized pain and at least 16 positive tender points (1990 American College of Rheumatology \[ACR\] criteria) * Body Mass Index (BMI) less than or equal to(=\<) 32 * Normal GH stimulation test (insulin) * Stable (\>= 3 months unchanged) standard treatment with amitriptyline (10-50 milligram per day \[mg/day\]) plus selective serotonin reuptake inhibitor (10-40 mg/day) plus tramadol (25-400 mg/day) * Active rehabilitation program during the previous year (at least 30 minutes/day) * Fibromyalgia Impact Questionnaire (FIQ) score \>=75 * IGF-1 serum level =\< 150 nanogram/milliliter (ng/mL) otherwise =\< 2 SD of the local lab normality) * Normal response to IGF-1 generation test * Chronic Fatigue Symptoms (Multidimensional Assessment of Fatigue \[MAF\]) * Effective anti-conception * Willingness to comply with the protocol * Written Informed consent Exclusion Criteria: * Major psychiatric condition * Rheumatic disease, including systemic lupus erythematosus (SLE) * Previous or current malignancies, active or inactive * Clinical history intracranial space occupying lesion * Reactive or secondary (rheumatoid arthritis \[RA\], osteoarthritis) fibromyalgia syndrome (FMS) * Antinuclear antibody (ANA) greater than or equal 1:80 * Abnormal Creatine phosphokinase (CPK) or aldolase serum levels * Not controlled thyroid disease in the last 3 months (free Thyroxine \[T4\] and Thyrotrophin-stimulating hormone \[TSH\] serum levels) * Diabetes mellitus * Adrenal gland disease (any abnormal cortisolemia, will be confirmed by 24-hour cortisoluria) * Pregnancy or breast feeding * Known to be hypersensitive to somatotropin or any of the excipients